Alzheimer's disease and type 2 diabetes: Hope for inhibitors against amyloid plaques
Effective therapeutics to counteract the formation of
amyloid plaques in Alzheimer's disease and type 2 diabetes are not yet
available. Scientists at the Technical University of Munich (TUM) have now come
a little bit closer to a solution: They have described a new class of designed
macrocyclic peptides that are highly potent inhibitors of amyloid formation.
Amyloid plaques, which are protein deposits, play a crucial
role in the development of Alzheimer's disease and type 2 diabetes. Several
teams of scientists around the world are working on finding ways to prevent
amyloid plaque formation in the human brain.
"Therefore, further investigations are now planned to
verify whether the MCIPs are also effective in in vivo models. Furthermore, the
MCIPs could also be suitable as templates for the development of small molecule
peptidomimetics (molecules mimicking peptide chains), which might also find
application as anti-amyloid drugs in Alzheimer's and type 2 diabetes.
Comments
Post a Comment